These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18198424)

  • 1. Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimer's disease.
    Tremblay C; Pilote M; Phivilay A; Emond V; Bennett DA; Calon F
    J Alzheimers Dis; 2007 Dec; 12(4):377-90. PubMed ID: 18198424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
    Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
    Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinctive temporal profiles of detergent-soluble and -insoluble tau and Aβ species in human Alzheimer's disease.
    Koss DJ; Dubini M; Buchanan H; Hull C; Platt B
    Brain Res; 2018 Nov; 1699():121-134. PubMed ID: 30102892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accumulation of transactive response DNA binding protein 43 in mild cognitive impairment and Alzheimer disease.
    Tremblay C; St-Amour I; Schneider J; Bennett DA; Calon F
    J Neuropathol Exp Neurol; 2011 Sep; 70(9):788-98. PubMed ID: 21865887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oligomeric Abeta in Alzheimer's disease: relationship to plaque and tangle pathology, APOE genotype and cerebral amyloid angiopathy.
    van Helmond Z; Miners JS; Kehoe PG; Love S
    Brain Pathol; 2010 Mar; 20(2):468-80. PubMed ID: 19725829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long night's journey into the day: amyloid-β imaging in Alzheimer's disease.
    Villemagne VL; Rowe CC
    J Alzheimers Dis; 2013; 33 Suppl 1():S349-59. PubMed ID: 22710919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cortical biochemistry in MCI and Alzheimer disease: lack of correlation with clinical diagnosis.
    Forman MS; Mufson EJ; Leurgans S; Pratico D; Joyce S; Leight S; Lee VM; Trojanowski JQ
    Neurology; 2007 Mar; 68(10):757-63. PubMed ID: 17339583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in the detergent-insoluble brain proteome linked to amyloid and tau in Alzheimer's Disease progression.
    Hales CM; Dammer EB; Deng Q; Duong DM; Gearing M; Troncoso JC; Thambisetty M; Lah JJ; Shulman JM; Levey AI; Seyfried NT
    Proteomics; 2016 Dec; 16(23):3042-3053. PubMed ID: 27718298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mild cognitive impairment and asymptomatic Alzheimer disease subjects: equivalent β-amyloid and tau loads with divergent cognitive outcomes.
    Iacono D; Resnick SM; O'Brien R; Zonderman AB; An Y; Pletnikova O; Rudow G; Crain B; Troncoso JC
    J Neuropathol Exp Neurol; 2014 Apr; 73(4):295-304. PubMed ID: 24607960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyroglutamylated amyloid-β is associated with hyperphosphorylated tau and severity of Alzheimer's disease.
    Mandler M; Walker L; Santic R; Hanson P; Upadhaya AR; Colloby SJ; Morris CM; Thal DR; Thomas AJ; Schneeberger A; Attems J
    Acta Neuropathol; 2014 Jul; 128(1):67-79. PubMed ID: 24861310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synaptic Loss, ER Stress and Neuro-Inflammation Emerge Late in the Lateral Temporal Cortex and Associate with Progressive Tau Pathology in Alzheimer's Disease.
    Buchanan H; Mackay M; Palmer K; Tothová K; Katsur M; Platt B; Koss DJ
    Mol Neurobiol; 2020 Aug; 57(8):3258-3272. PubMed ID: 32514860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain amyloid-β oligomers in ageing and Alzheimer's disease.
    Lesné SE; Sherman MA; Grant M; Kuskowski M; Schneider JA; Bennett DA; Ashe KH
    Brain; 2013 May; 136(Pt 5):1383-98. PubMed ID: 23576130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.
    Jack CR; Wiste HJ; Vemuri P; Weigand SD; Senjem ML; Zeng G; Bernstein MA; Gunter JL; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS;
    Brain; 2010 Nov; 133(11):3336-48. PubMed ID: 20935035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice.
    Murphy MP; Beckett TL; Ding Q; Patel E; Markesbery WR; St Clair DK; LeVine H; Keller JN
    Neurobiol Dis; 2007 Sep; 27(3):301-11. PubMed ID: 17651976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topographical Overlapping of the Amyloid-β and Tau Pathologies in the Default Mode Network Predicts Alzheimer's Disease with Higher Specificity.
    Hojjati SH; Feiz F; Ozoria S; Razlighi QR;
    J Alzheimers Dis; 2021; 83(1):407-421. PubMed ID: 34219729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative proteomics of tau and Aβ in detergent fractions from Alzheimer's disease brains.
    Mukherjee S; Dubois C; Perez K; Varghese S; Birchall IE; Leckey M; Davydova N; McLean C; Nisbet RM; Roberts BR; Li QX; Masters CL; Streltsov VA
    J Neurochem; 2023 Feb; 164(4):529-552. PubMed ID: 36271678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
    Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Neuropathological Markers in the Parietal Cortex With Antemortem Cognitive Function in Persons With Mild Cognitive Impairment and Alzheimer Disease.
    Tremblay C; François A; Delay C; Freland L; Vandal M; Bennett DA; Calon F
    J Neuropathol Exp Neurol; 2017 Feb; 76(2):70-88. PubMed ID: 28158844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.
    Lue LF; Kuo YM; Roher AE; Brachova L; Shen Y; Sue L; Beach T; Kurth JH; Rydel RE; Rogers J
    Am J Pathol; 1999 Sep; 155(3):853-62. PubMed ID: 10487842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.